• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chin

Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chin

来源 :第11届中国介入心脏病学大会 | 被引量 : 0次 | 上传用户：mahuihui
【摘 要】
：
Background Risk stratification schemes assessing stroke and thromboembolism (TE) and bleeding relating to atrial fibrillation (AF) have largely been derived and validated in Western populations.We ass
【作 者】
：
GUO Yu-tao Gregory Y Hlip Stavros Apostolakis Andrew D Blann WANG Hai-jun ZHAO Xiao-ning ZHANG Yu ZHANG De-xian MA Jing-ling WANG Yu-tang 
【机 构】
：
Department of Geriatric Cardiology,Chinese PLA General Hospital,Beijing,China
【出 处】
：
第11届中国介入心脏病学大会
【发表日期】
：
2013年7期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background Risk stratification schemes assessing stroke and thromboembolism (TE) and bleeding relating to atrial fibrillation (AF) have largely been derived and validated in Western populations.We assessed risk factors that constitute scores for assessing stroke/TE (CHADS2, CHA2DS2-VASc) and bleeding (HAS-BLED), and the predictive value of these scores in a large cohort of Chinese patients with AF.
其他文献
Clinical outcomes in Chinese patients with long lesion or small vessel or multivessel disease receiv
Background The efficacy and safety of XIENCE V(R) everolimus-eluting coronary stems (XIENCE V, Abbott Vascular,Santa Clara, CA, USA) have been demonstrated in pre-marketing and post-marketing studies
会议
Five-year clinical follow-up of unprotected left main bifurcation lesion stenting: one-stent versus
Baekgraund The present study aimed to compare the long-term (five-year) safety and efficacy between the one-stent,two-stent and double-kissing (DK) crush strategies, utilising drug-eluting stents, for
会议
TARGET I: A prospective multicenter randomized trial assessing the safety and effectiveness of FIREH
Background Durable polymers used for early-generation drug-eluting stents potentially contribute to persistent inflammation, delayed endothelial healing, and late DES thrombosis.The study aimed to eva
会议
Three hours continuous injection of adenosine improved left ventricular function and infarct size in
Background Reperfusion might be associated with undesired effect-ischemia reperfusion injury.The present study aimed at investigating the effect of intravenous adenosine on clinical outcomes in patien
会议
One-stop hybrid coronary revascularization versus coronary artery bypass graft and percutaneous coro
Background One-stop hybrid coronary revascularization (HCR) has emerged to be a feasible and attractive alternative to coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI)
会议
A new generation biodegradable polymer-coated sirolimus-eluting stents in “real-world” practice:fina
Background The CREATE is a post-marketing surveillance multicenter registry that demonstrated satisfactory angiographic and clinical (at 18 months) outcomes of a biodegradable polymer based sirolimus-
会议
Long-term outcomes of complete versus incomplete revascularization after drug-eluting stent implanta
Background A limited number of studies on the impact of complete revascularization (CR) vs.incomplete revascularization (IR) on long-term outcomes in patients with multivessel coronary disease (MVD) i
会议
Double-kissing culotte stenting technique in coronary bifurcation disease: angiographic follow-up an
Background Percutaneous treatment of coronary bifurcation disease remains challenging.Optimal treatment with PCI for bifurcation lesions has yet to be achieved.In patient subsets in which a two-stent
会议
Effect of thrombolytic therapy and percutaneous transluminal coronary intervention on the incidence
Background Ventricular free wall rupture (or free wall rupture, FWR) is a catastrophic mechanical complication of acute myocardial infarction (AMI) occurring in 0.9％ to 4.5％ of patients admitted to th
会议
Initial experience of occluding special type patent ductus arterioses using the Amplatzer vascular p
Background Occluders licensed for clinical use are not fit for some special Krichenko E patent ductus arterioses(PDA).The Amplatzer vascular plug I (Plug I) has not been licensed for use for closure o
会议